Towards Healthcare

miRNA Sequencing and Assay Key Players | Innovation and Product Evolution | Market Entry and Expansion Strategies | Investment and Capital Allocation | Technology Commercialization | Market Trends Analysis | Future Market Positioning

Date: January 2025

miRNA Sequencing and Assay Companies and Market Forecast

The global miRNA sequencing and assay market size is calculated at US$ 391.73 in 2024, grew to US$ 443.95 million in 2025, and is projected to reach around US$ 1369.11 million by 2034. The market is expanding at a CAGR of 13.33% between 2024 and 2034.

miRNA Sequencing and Assay Market Companies

Top Companies in the miRNA Sequencing and Assay Market are:

  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • QIAGEN
  • PerkinElmer, Inc.
  • Abcam plc
  • New England Biolabs
  • Takara Bio Inc.
  • Lexogen GmbH
  • Norgen Biotek Corp.
  • Maravai LifeSciences
  • HTG Molecular Diagnostics, Inc.
  • Meridian Bioscience, Inc.
  • System Biosciences, LLC

International Trade Data for Activated Carbon and Similar Preparations

CONSIGNEE_NAME SHIPPER_NAME LOADING_PORT SUMOFQUANTITY SUMOFWEIGHT
EUCATEX OF NORTH AMERICA INC EUCATEX INDUSTRIA E COMERCIO LTDA 35177, SAO PAULO 901730 5319866664
PEREZ TRADE COMPANY SYLVAMO EXPORT LTDA 30107, CARTAGENA 113014 3696665
NATIONAL PRESTO IND INC LEERAY ENTERPRISES LIMITED 57078, YANTIAN 35314 148924
EUCATEX OF NORTH AMERICA INC EUCATEX INDUSTRIA E COMERCIO LTDA 35177, SAO PAULO 23800 281520
NATIONAL PRESTO IND INC LEERAY ENTERPRISES LIMITED 57078, YANTIAN 20141 75800
PEREZ TRADE COMPANY SYLVAMO EXPORT LTDA 35177, SAO PAULO 17528 1089922
EUCATEX OF NORTH AMERICA INC EUCATEX INDUSTRIA E COMERCIO LTDA 35177, SAO PAULO 16000 148102
NATIONAL PRESTO IND INC LEERAY ENTERPRISES LIMITED 57078, YANTIAN 15505 57422
EUCATEX OF NORTH AMERICA INC EUCATEX INDUSTRIA E COMERCIO LTDA 30107, CARTAGENA 15200 227661
SHAW INDUSTRIES GROUP JIANGSU KENTIER WOOD CO LIMITED 57020, NINGPO 13440 625268

Latest Announcements by Industry Leaders

In March 2024, since its start in the 1970s, genetic sequencing has advanced significantly, according to Dr. Kuo, the CEO of the business. One of the most intriguing new advances in biotechnology is long-read RNA sequencing, which is driving the industry to move away from short-read sequencing. We think that a fresh generation of biotechnology advances might be accelerated by our solution. Its potential is demonstrated by the support of some of the top life science investors in the UK. The money will support our efforts to uncover the hidden realm of RNA and open up fascinating new uses.

Recent Developments in the miRNA Sequencing and Assay Market

  • In October 2024, Sanofi made a strategic equity investment in Resalis Therapeutics to expedite RES-010's clinical trial progress. Resalis Therapeutics is positioned as a prospective participant in the RNA therapeutics market due to its emphasis on miRNA-based medicines. The business is well-positioned to significantly advance the treatment of metabolic illnesses because of its creative strategy and the increasing backing of important industry partners.
  • In October 2024, American scientists Victor Ambros and Gary Ruvkun were named the 2024 Nobel Prize laureates in Physiology or Medicine for their research on microRNA. Their findings provide insight into the origins of sophisticated life on Earth and the diverse range of tissues that make up the human body.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com